Vaxcyte, Inc. $PCVX Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans decreased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 67.9% in the third quarter, Holdings Channel reports. The firm owned 7,184 shares of the company’s stock after selling 15,205 shares during the period. Thrivent Financial for Lutherans’ holdings in Vaxcyte were worth $259,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Edgestream Partners L.P. purchased a new stake in Vaxcyte in the second quarter valued at about $1,610,000. Federated Hermes Inc. grew its stake in shares of Vaxcyte by 6,856.3% during the third quarter. Federated Hermes Inc. now owns 18,156 shares of the company’s stock worth $654,000 after acquiring an additional 17,895 shares during the last quarter. State of New Jersey Common Pension Fund D increased its holdings in shares of Vaxcyte by 36.4% during the second quarter. State of New Jersey Common Pension Fund D now owns 55,477 shares of the company’s stock valued at $1,804,000 after acquiring an additional 14,799 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Vaxcyte in the 3rd quarter valued at approximately $2,640,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Vaxcyte in the 2nd quarter valued at approximately $1,359,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Elvia Cowan sold 11,623 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the transaction, the senior vice president owned 14,534 shares of the company’s stock, valued at $696,469.28. The trade was a 44.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the completion of the sale, the insider owned 23,928 shares in the company, valued at $1,117,198.32. The trade was a 28.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on PCVX shares. Needham & Company LLC upped their price target on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. BTIG Research reissued a “buy” rating and set a $85.00 price objective on shares of Vaxcyte in a report on Monday, November 10th. Guggenheim reissued a “buy” rating and issued a $116.00 target price on shares of Vaxcyte in a research report on Monday, February 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. Finally, Leerink Partners set a $77.00 price target on Vaxcyte and gave the company an “outperform” rating in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $93.83.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $56.17 on Thursday. The company’s fifty day moving average price is $49.52 and its 200-day moving average price is $42.61. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $84.10. The firm has a market capitalization of $7.35 billion, a P/E ratio of -11.61 and a beta of 1.33.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.